California - based Global Oncology has struck a deal with Massachusetts biotechnology company bluebird bio , in order to develop cell therapy cancer treatments . Gritstone will use its proprietary EDGE AI platform to identify and supply 10 tumor - specific proteins , as well as selected natural T - cell receptors , which bluebird bio will then use in its cell therapy platforms . Grtistone will receive $ 20 m up - front funding and $ 10 m in series C preferred equity investment as part of the deal .
California-based Gritstone Oncology has struck a deal with Massachusetts biotechnology company bluebird bio, in order to develop cell therapy cancer treatments. Gritstone will use its proprietary EDGE AI platform to identify and supply 10 tumor-specific targets, as well as selected natural T-cell receptors, which bluebird bio will then use in its cell therapy platforms. Grtistone will receive $20m up-front funding and $10m in series C preferred equity investment as part of the agreement.